NDUFA10
ENSG00000130414
Target class
Enzyme
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-42k
- Target name
- NDUFA10
- Gene name
- NADH:ubiquinone oxidoreductase subunit A10
- Gene symbol
- NDUFA10
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial (Complex I-42kD) (CI-42kD) (NADH-ubiquinone oxidoreductase 42 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits|Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 95.47
- Tissue specificity (Gini)
- 0.178
- Tissue specificity (tau)
- 0.623
- KEGG gene identifiers
- hsa:4705
- Protein interaction confidence
- 0.937857
- Protein interaction partners
- 91
- R-HSA-611105
- R-HSA-6799198
- End position
- 240025743
- Start position
- 239892450
- Chromosome
- 2
- Strand
- Reverse
- Mitochondrion matrix .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.623114
- Expression inequality (Gini)
- 0.177626
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 95.47
- Brain - Cerebellum
- 92.41
- Nerve - Tibial
- 52.41
- Heart - Left Ventricle
- 50.09
- Cells - EBV-transformed lymphocytes
- 47.7
Expression in transcripts per million
- Brain - Cerebellar Hemisphere95.47
- Brain - Cerebellum92.41
- Nerve - Tibial52.41
- Heart - Left Ventricle50.09
- Cells - EBV-transformed lymphocytes47.7
- Ovary46.81
- Adrenal Gland46.59
- Skin - Sun Exposed (Lower leg)46.56
- Skin - Not Sun Exposed (Suprapubic)46.04
- Cells - Cultured fibroblasts44.24
- Brain - Frontal Cortex (BA9)42.67
- Heart - Atrial Appendage41.44
- Fallopian Tube41.25
- Uterus41.14
- Brain - Cortex40.36
- Muscle - Skeletal39.86
- Colon - Transverse39.49
- Testis39.39
- Pituitary39.35
- Vagina38.78
- Thyroid38.75
- Cervix - Endocervix38.56
- Esophagus - Mucosa37.99
- Cervix - Ectocervix37.96
- Esophagus - Muscularis37
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor